



49th Annual Meeting
April 6-8, 2025
Loews Philadelphia

Saturday, April 5

- 8:00 am - 12:00 pm **Boot Camp for New Associate Directors and Program Leaders**
An interactive forum for program leaders and associate directors attending the AD/PL Workshop who are in the **first year of their role**, this additional morning session will cover topics such as what is an NCI-designated cancer center, cancer center roles and responsibilities, CCSG insights and more.
- 1:00 pm- 7:30 pm Associate Director/Program Leader (AD/PL) Workshop
- 7:30 pm - 8:30 pm AD/PL Reception

Sunday, April 6

- 8:00 am - 12:00 pm AD/PL Workshop
- 12:00 pm - 1:00 pm Early Career Session
- 1:15 pm - 2:15 pm Early Career Session
- 2:30 pm - 4:00 pm **Concurrent Sessions**
- Community & Science Session
Topic and Speakers TBD
- NCI Cancer Control and Population Sciences Program Project Grant (P01) Workshop**
This workshop will promote the P01 and provide technical assistance to senior investigators and experienced investigative teams interested in learning about the P01 grant application. During this session, attendees will learn about DCCPS scientific priorities for large program projects; discuss components of a P01 application, timelines, and example funded applications. Attendees will learn about the P01 application process, tips and suggestions for success, and have the opportunity to meet with NCI, DCCPS scientific staff.
- 4:15 pm - 4:45 pm Conference Welcome & Presidential Address
Anita Kinney, PhD, RN, FAAN, FABMR, Rutgers Cancer Institute of New Jersey
- 4:45 pm - 5:15 pm Cullen Award Address
- 5:15 pm - 5:45 pm Fraumeni Award Address
- 5:45 pm - 7:15 pm Poster Session/Reception 1

Monday, April 7

8:00 am - 9:15 am **Concurrent Breakfast Sessions**

9:30 am – 10:15 am **Concurrent Sessions**

Looking Back, Thinking Forward 1: The Untapped Potential of Lung Cancer Screening

Chairs: Dejana Braithwaite, PhD, MSc, University of Florida and Karen Wernli, PhD, Kaiser Permanente Washington Health Research Institute

Speaker: Jamie Studts, PhD, University of Colorado Cancer Center, followed by three flash talks selected from submitted abstracts

The purpose of this session is to provide an overview of the history, successes, challenges, and future directions of lung cancer screening in the US. Interventions and policies to promote informed/shared decision-making and behavior change among patients and clinicians regarding prevention, screening, and survivorship of lung cancer will be discussed.

Symposium 1: Integrating Social Determinants of Health to Advance Molecular Epidemiology

Chairs: Shaneda Warren Andersen, PhD, University of Wisconsin-Madison and Nur Zeinomar, PhD, MPH, Rutgers Cancer Institute

Speakers: Meira Epplein, PhD, Duke University School of Medicine and Adana Llanos, PHD, MPH, Columbia University Mailman School of Public Health

This session will explore how integrating social determinants into molecular epidemiology studies deepens our understanding of cancer risk and prognosis. The invited speakers will present examples from the field – including gastric cancer and breast cancer – and illustrate how measures of social determinants incorporated into molecular epidemiological studies can provide a more holistic understanding of cancer. This session will also highlight the implications for preventive oncology and discuss strategies for including diverse voices in research and study design.

10:30 am - 11:15 am **Concurrent Sessions**

Looking Back, Thinking Forward 2: Evolving Approaches and New Directions in Cancer Prevention and Screening Equity

Chairs: Parisa Tehranifar, DrPH, Columbia University and Michael Scheurer, PhD, MPH, Baylor College of Medicine

Speaker: Electra Paskett, PhD, The Ohio State University, followed by three flash talks selected from submitted abstracts

Over recent decades, efforts to understand and address cancer health equity have evolved from focusing on individual level factors to embracing a multilevel approach. Research increasingly recognizes the complex interplay of social determinants of health, including racism, socioeconomic resources, gender identity, geography, and neighborhood contexts. This session explores the progression of cancer disparities research and highlight emerging work on the role of structural barriers to health and community-engaged research in advancing cancer health equity.

Symposium 2: Misinformation and Infodemics: Implications for Cancer Control

Chair: K. "Vish" Viswanath, PhD, Harvard T. H. Chan School of Public Health and the Dana-Farber Cancer Institute

Speakers: Tina Purnat, MS, Harvard T. H. Chan School of Public Health and Roberta Braga, MA, Digital Democracy Institute

One consequence of the spread and penetration of information and communication technologies is the generation, processing and dissemination of enormous amounts of information and data. The 5 Vs—*volume, velocity, variety, veracity, and value* have posed a

central challenge in the form of spread of information and misinformation outpacing societal capacity to manage the flow of information and understand the consequences for cancer control. The COVID pandemic has amplified these concerns, precipitating engagement by researchers, policy makers, and practitioners to address the infodemic and misinformation. This session will discuss the notion of infodemic, misinformation and its implications for cancer control by speakers who have been leaders in studying misinformation and developing ways to address it.

- 11:30 am - 1:00 pm Community & Science Lunch Session
- 1:15 pm - 2:15 pm **Best of ASPO Sessions**
Oral presentations chosen from submitted abstracts
- 2:30 pm - 3:30 pm **Best of ASPO Sessions**
Oral presentations chosen from submitted abstracts
- 3:45 pm - 4:30 pm **Keynote Session**
Kimryn Rathmell, MD, PhD
National Cancer Institute Director
- 4:45 pm - 5:15 pm ASPO Business Meeting
- 5:30 pm - 7:00 pm Poster Session/Reception 2

Tuesday, April 8

- 8:00 am - 9:15 am ***Concurrent Breakfast Sessions***
- 9:30 am – 10:15am ***Concurrent Sessions***

Looking Back, Thinking Forward 3: Evolution of Chemoprevention and Early Discovery

Chair: Jessica Faupel-Badger, PhD, MPH, National Cancer Institute

Speaker: Margie Clapper, PhD from Fox Chase Cancer Center, followed by three flash talks selected from submitted abstracts

The field of cancer prevention has evolved from large phase III trials focused on broad populations to smaller, focused trials tailored to high-risk populations. This evolution has been possible through advances in understanding cancer's etiology, more precisely defining populations at risk, and development of new agents, including an emphasis on immunoprevention. This session will briefly highlight past approaches and contrast this with new strategies at this exciting time for cancer prevention clinical trials.

Symposium 3: Pragmatic Trials and Implementation Science in Cancer Prevention and Control

Chair: Maria Fernandez, PhD, UTHealth Houston

Speakers: Simon Craddock Lee, PhD, MPH, University of Kansas Medical Center and Katharine Rendle, PhD, University of Pennsylvania

This session will focus on using pragmatic trials to expand reach, equity, and implementation of cancer screening and leveraging implementation science to optimize cancer healthcare delivery in safety-net settings, urban and rural. The session will address the use of mixed-method multilevel evaluation in pragmatic trial design and research partnerships that foster learning health systems and other collaborations that enable science to support community priorities.

10:30 - 11:15 am

Concurrent Sessions

Looking Back, Thinking Forward 4: Advancing Equity in Cancer Care Delivery

Chairs: Albert Farias, PhD, MPH, University of Southern California and Lorna Haughton McNeil, MD Anderson Cancer Center

Speaker: Karen Winkfield, MD, PhD, Vanderbilt University Ingram Cancer Center, *followed by three flash talks selected from submitted abstracts*

Gaps in the quality of cancer care delivery along the continuum of care exist for individuals based on race, ethnicity, gender identity and sexual orientation, place of residence, disability status, and socioeconomic status. The goal of the session is to identify clinically important and sustained modifications to the structures and processes of health systems to improve clinical outcomes, enhance patient experiences, and optimize value of care. This session will review the drivers of these inequities and focus on contemporary solutions for addressing them. Action-oriented approaches include policy, multidisciplinary care delivery transformation, standardized assessment measures, and evidence-based practice change. Confirmed senior investigator:

Symposium 4: New Frontiers in Artificial Intelligence, Machine Learning, and Data Science in Cancer Prevention and Intervention

Chairs: Suzanne O'Neill, PhD, Lombardi Cancer Center and Anita Y. Kinney, PhD, RN, Rutgers Cancer Institute

Speakers: Warren Kibbe, PhD, National Cancer Institute and Elizabeth Handorf, PhD, Rutgers Cancer Institute

The session will focus on computationally intensive and cutting-edge machine learning methods for high-dimensional data as well as data representation for clinical trials and improving data interoperability between electronic health records and decision support algorithms.

11:30 am - 12:45 pm

Lunch Session TBD

1:00 pm - 2:00 pm

Best of ASPO Sessions

Oral presentations chosen from submitted abstracts.

2:15 pm - 3:15 pm

Best of ASPO Sessions

Oral presentations chosen from submitted abstracts